RA0400

antibody from Oursmab

Targeting: IL6 BSF2, HGF, HSF, IFNB2, IL-6

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0400

Provider

Oursmab

Product name

Olokizumab (Biosimilar Reference Antibody) (IL6)

Antibody type

Monoclonal

Description

Olokizumab is a humanized monoclonal antibody that specifically targets interleukin-6 (IL-6), a key pro-inflammatory cytokine. Unlike some other anti-IL-6 therapies that block the IL-6 receptor (e.g., tocilizumab), olokizumab binds directly to the IL-6 cytokine itself, preventing it from interacting with both the membrane-bound and soluble forms of the IL-6 receptor (IL-6R). This inhibition blocks downstream JAK/STAT and MAPK signaling, reducing systemic and local inflammation. It is approved in Russia for the treatment of moderate-to-severe rheumatoid arthritis (RA) in adults who have had an inadequate response to disease-modifying anti-rheumatic drugs (DMARDs). It is administered via subcutaneous injection.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.